Chiang, Tung LinTung LinChiangSun, Yi ChenYi ChenSunWu, Jo HsuanJo HsuanWuHsieh, Ying TungYing TungHsiehWEI-LUN HUANGWEI-LI CHEN2023-03-012023-03-0120230950222Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/628821Background: Graft-versus-host disease (GVHD) is one of the major complications of allogenic haematopoietic stem cell transplantation (HSCT). The manifestation of ocular GVHD (oGVHD) is variable and may involve cornea, lacrimal gland, conjunctiva, eyelid, and/or nasolacrimal duct. We reviewed and summarized the current managements of oGVHD with specific focus on the emerging therapeutic advances. Methods: PubMed, Web of Science, and Google Scholar were searched for relevant literatures published within 20 years. Keywords used included “Graft-Versus-Host Disease”, “GVHD”, “ocular”, “ocular surface”, “ocular GVHD”, “oGVHD”, “dry eye”, “keratitis”, etc. Results: Current managements of oGVHD can be classified into topical immunosuppressants, local tear-preservatory treatments, local non-pharmacological/surgical interventions, and systemic treatments. Additionally, some innovative therapies with promising treatment effects have been proposed, including topical target therapies, epitheliotrophic and neurotrophic treatments, recombinant DNase eye drops, mesenchymal stromal cell injection, and more. Conclusions: Clinical managements of oGVHD are administered in a symptom-based, stepwise manner. The advances in innovative therapies may help improve clinical outcomes, and it is essential that physicians stay updated with these novel treatment options.enSEVERE DRY EYE; CONSENSUS DEVELOPMENT PROJECT; SUPERIOR LIMBIC KERATOCONJUNCTIVITIS; BONE-MARROW-TRANSPLANTATION; SPLEEN TYROSINE KINASE; NERVE GROWTH-FACTOR; AUTOLOGOUS SERUM; CLINICAL-TRIALS; CELL TRANSPLANTATION; TACROLIMUS OINTMENTjournal article10.1038/s41433-022-02288-9363335342-s2.0-85141423131WOS:000878930600001https://api.elsevier.com/content/abstract/scopus_id/85141423131